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Fatty acid binding protein 5 (FABP5) delivers ligands from the cytosol directly to the nuclear receptor PPARβ/δ and thus facilitates
the ligation and enhances the transcriptional activity of the receptor. We show here that expression levels of both FABP5 and
PPARβ/δ are correlated with the tumorigenic potential of prostate cancer cell lines. We show further that FABP5 comprises a
d i r e c tt a r g e tg e n ef o rP P A R β/δ and thus the binding protein and its cognate receptor are engaged in a positive feedback loop. The
observations demonstrate that, similarly to eﬀects observed in mammary carcinomas, activation of the FABP5/PPARβ/δ pathway
induces PPARβ/δ target genes involved in cell survival and growth and enhances cell proliferation and anchorage-independent
growth in prostate cancer cells. Furthermore, the data show that downregulation of either FABP5 or PPARβ/δ inhibits the growth
of the highly malignant prostate cancer PC3M cells. These studies suggest that the FABP5/PPARβ/δ pathway may play a general
role in facilitating tumor progression and that inhibition of the pathway may comprise a novel strategy in treatment of cancer.
1.Introduction
The current treatment of prostate cancer relies on a com-
bination of androgen ablation and radiation/chemotherapy
but tumors often relapse in a more aggressive hormone-
refractory form. There is thus a clear need for a better
understanding of the molecular mechanisms involved in the
malignant progression of prostate cancer which may lead to
new therapies [1, 2].
The vitamin A metabolite retinoic acid (RA) controls
multiple biological processes by virtue of its ability to reg-
ulate gene transcription. These activities are mediated by the
ligand-activated transcription factors retinoic acid receptors
(RARs) [3, 4] and peroxisome proliferator activated receptor
β/δ (PPARβ/δ)[ 5, 6]. Activation of RAR by RA results in
up-regulation of target genes that promote apoptosis, cell
cycle arrest, and diﬀerentiation, for example, the cell cycle
regulator Btg2 and the apoptotic gene caspase 9 [7, 8].
Hence, in cancers where RA activates RAR, it functions as a
potent anticarcinogenic agent [9, 10]. However, target genes
for the alternate RA receptor, PPARβ/δ, include genes that
promote cell survival and proliferation, for example, the
survivalfactorPDK1andtheangiogenicgrowthfactorVEGF
[11, 12] and thus, in cells in which RA activates this receptor,
it promotes rather than inhibits growth [5, 13].
The partitioning of RA between its two receptors is
regulated by two members of the family of intracellular
lipid binding proteins (iLBPs): fatty acid binding protein
5 (FABP5), which delivers RA from the cytosol to nuclear
PPARβ/δ and cellular RA-binding protein II (CRABP-II)
which shuttles it to RAR [7, 8, 14–18]. In accordance, it
has been shown that RA inhibits the growth of mammary
carcinomas that express a high CRABP-II/FABP5 ratio but
facilitates proliferation of mammary carcinomas in which
this ratio is low [5, 13, 15, 19].
FABP5 and its cognate receptor PPARβ/δ thus appear
to function as oncogenes, and it has been suggested that
inhibition of their transcriptional activities may comprise a
novel strategy for treatment of some cancers [12, 13].
A question that arises from these observations is whether
activation of the FABP5/PPARβ/δ path underlies tumor
development in cancers other than speciﬁc breast cancers. In
support of this notion, it has been reported that the expres-
sion of FABP5 is upregulated in carcinomas of the pancreas,2 PPAR Research
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Figure 1:ProstatecancerprogressionisaccompaniedbyupregulationofFABP5/PPARβ/δ expressionandsignalling.(a)Bottom:Expression
levels of FABP5 mRNA in denoted cell lines were measured by Q-PCR. Top: Level of FABP5 protein in denoted cell lines assessed
by immunoblots. (b) Bottom: Expression levels of PDK-1 and PPARβ/δ mRNA in denoted cell lines were measured by Q-PCR. Top:
Immunoblots of PDK1 in denoted cell lines. Data are mean±S.D. (n = 3). ∗P<. 02 versus 22Rv.1. (Paired T test). Immunoblots were
repeated three times with similar results.
breast, bladder, and prostate [20]. It was also reported that
FABP5 can serve as a prognostic marker and that it induces
metastasis of prostate cancer [20, 21]. This activity could be
traced to the ability of FABP5 to upregulate the expression of
VEGF [22, 23].
The present study was undertaken in order to examine
whether FABP5 and PPARβ/δ are involved in regulation
of prostate cancer cell growth and to obtain insight into
mechanisms by which the expression of FABP5 is regulated.
We show that PPARβ/δ directly induces the expression of
FABP5 through a functional PPRE within the promoter
region of the FABP5 gene. We show further that activation
of the FABP5/PPARβ/δ pathway enhances the proliferation
of malignant prostate cancer cell line PC3M, and that
downregulation of either protein inhibits the growth of these
cells. The data reveal the existence of a positive feedback
loop that enhances the transcriptional activities of the
FABP5/PPARβ/δ pathway in prostate cancer cells, and they
indicate that these activities support prostate carcinoma cell
proliferation and tumorigenicity.
2. Results
2.1. Prostate Cancer Progression Is Accompanied by Upreg-
ulation of FABP5/PPARβ/δ Expression and Signalling. To
begin to examine whether FABP5 and PPARβ/δ may play
a role in prostate cancer cell growth, the expression levels
of these genes were assessed in three prostate cancer cell
lines, the benign PNT-2 cells, the mildly oncogenic 22Rv1
cells, and the highly malignant PC3M cells [24–27]. The
levels of FABP5 and PPARβ/δ mRNA were measured by
quantitative real-time PCR (Q-PCR) and FABP5 protein
expression was assessed by immunoblots. The data (Figures
1(a) and 1(b)) indicated that expression of both FABP5 and
PPARβ/δ markedly higher in PC-3M cells. Correspondingly,
expression of the direct PPARβ/δ target gene PDK1 [28], a
kinase involved in activation of survival pathways, was also
elevated in PC-3M cells (Figure 1(b)). Hence, the expression
as well as the transcriptional activity of the FABP5/PPARβ/δ
pathway appear to correlate with the tumorigenic potential
of these cell lines.
2.2. FABP5 Is a Direct Target Gene for PPARβ/δ. To examine
whether the expression of FABP5 may be controlled by
PPARβ/δ, PC3M cells were treated with the synthetic
PPARβ/δ-selective ligand GW0742. Eﬀects of the treatment
ontheexpressionoftwoknownPPARβ/δ targetgenes,PDK1
and adipose diﬀerentiation-related protein (ADRP [29]),
and on the expression of FABP5 was assessed by Q-PCR.
GW0742 upregulated the expression of PDK1 and ADRP
in these cells (Figure 2(a)). Similarly to the response of
these direct PPARβ/δ target genes, GW0742 treatment also
resulted in upregulation of FABP5 mRNA (Figure 2(a))a n d
protein (Figure 2(b)). A similar response was observed in
22Rv1 cells (Figure 2(c)). Decreasing the expression level
of PPARβ/δ by transfecting PC3M cells with an expressionPPAR Research 3
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Figure 2: Activation of PPARβ/δ results in upregulation of FABP5. (a) PC3M cells were treated with GW0742 (1μM, 4h). Expression of
FABP5, PDK1, ADRP, and VEGF were assessed by Q-PCR. The data were normalized to the untreated control. (b, c) Denoted cells were
treated with 1μM( a )o r2μM (b) GW0742 for 16h. Left panels, immunoblots of FABP5 in untreated versus GW0742-treated cells. Right
panel: Densitometry analyses depicting changes in FABP5 expression upon treatment with GW0742 in three independent experiments
(mean±S.D.). (d, e) PC3M cells were transfected with vectors harboring SiScramble or PPARβ/δ siRNA. Three days later, expression of
FABP5, PPARβ/δ, and VEGF mRNA in were measured by Q-PCR (d) and FABP5 expression was assessed by immunoblot (e). (f) PC3M
cells were stably transfected with an empty vector (PGIPZ), or a vector harbouring shFABP5. Expression levels of FABP5, PPARβ/δ,a n d
VEGF mRNA were measured by Q-PCR. ∗P<. 05 versus nontreated controls.
vector harbouring siRNA towards the receptor downregu-
lated the expression of the direct PPARβ/δ target gene VEGF
as well as the expression of FABP5 (Figures 2(d) and 2(e)). In
accordancewith theknownfunctionofFABP5insupporting
PPARβ/δ function, decreasing the expression of the binding
protein using a lentoviral vector encoding FABP5shRNA
downregulated the expression of VEGF (Figure 2(f)).
ToexaminewhetherFABP5isadirecttargetforPPARβ/δ
or whether the response reﬂects secondary events, the eﬀect
of the PPARβ/δ-selective ligand GW0742 on FABP5 expres-
sion was examined in the presence of the protein synthesis
inhibitor cycloheximide. PC3M cells were pretreated with
vehicle or cycloheximide for 10min prior to addition of
the GW0742. Cells were incubated for 4hr. and the level of
FABP5 mRNA measured by Q-PCR. GW0742 induced the
expression of FABP5 both in the absence and in the presence
of cycloheximide (Figure 3(a)), indicating that the eﬀect did
not require de novo protein synthesis raises the possibility
that FABP5 is a direct target gene for PPARβ/δ in PC3M
prostate cancer cells.
2.3. The FABP-5 Promoter Contains a Functional PPRE.
T h es o f t w a r eN u b i s c a n( http://www.nubiscan.unibas.ch/)
was used to identify PPAR response elements (PPRE) that
may mediate the ability of PPARβ/δ to upregulate FABP5.
FourpotentialPPREswereidentiﬁedwithin900bpupstream
from the FABP5 transcription start site (Figure 3(b), PPRE1-
PPRE4). The region was cloned into a luciferase reporter
construct, and transcriptional activation assays were carried
out. PC3M cells were transfected with a luciferase reporter
driven by the minimal prolactin promoter (prl-luc) or a
luciferase reporter containing the 900bp sequence of the
FABP5 promoter (FABP5-luc). Cells were also cotransfected
with an expression vector for PPARβ/δ and with a plasmid
encoding β-galactosidase, which served as a transfection
control. Cells were treated with vehicle or GW0742 for4 PPAR Research
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Figure 3 :F A B P 5i sad i r e c tt a r g e tg e n ef o rP P A R β/δ. (a) PC3M cells were treated with cycloheximde (20μg/mL) for 10min prior to addition
of GW0742 (1μM, 4h). Expression of FABP5 mRNA was measured by Q-PCR. Data are mean±S.D. (n = 3). ∗P<. 05 versus nontreated
control. (b) Location of putative PPREs in the FABP5 promoter. (c) Transcriptional activation assays utilizing a luciferase reporter driven
by a 900bp region of the FABP5 promoter which encompasses the four putative PPREs (5 promoter). In the mutant reporter construct (5
promoter/PPRE4m),theAGCTCAsequenceinPPRE4wasexchanged toAGCTTT.PC3Mcellswerecotransfectedwiththedenotedreporter
and an expression vector for β-galactosidase. 24h later, cells were treated with vehicle or GW0742 and cultured for 24hr. Luciferase activity
was measured and normalized to the activitiy of b-galactosidase. Data are mean±S.D. (n = 3). Inset: Luciferase assays carried out with a
luciferase reporter driven by 3 consensus PPREs. (d) Chromatin immunoprecipitation assays in denoted cell lines. Immunoprecipitations
were carried out using denoted antibodies and the PPRE4 region of the FABP5 promoter ampliﬁed by PCR. Bottom panel: quantiﬁcation of
3 independent ChiP assays (mean±SEM).
24hr, lysed, and lysates assayed for luciferase activity. The
data (Figure 3(c)) show that the 900bp promoter region of
FABP5 enhanced the basal activity of the reporter as well as
responded to treatment with GW0742 in a dose-dependent
fashion, indicating the presence of a functional PPRE. To
more precisely localize the PPRE, transcriptional activation
assays were carried out utilizing reporter constructs in
which the putative response elements were individually
mutated. Mutation of the most proximal element, PPRE4,
abolished the ability of the reporter to respond to the ligand
(Figure 3(c)), indicating that the element is necessary of
PPARβ/δ-mediated upregulation of FABP5. In agreement,
chromatin immunoprecipitation assays (ChIP) indicated
that both PPARβ/δ and its heterodimerization partner RXR
are recruited to PPRE4 (but not the other putative response
elements) in both 22Rv1 and PC3M cells (Figure 3(d)).
Taken together, the data demonstrate that PPARβ/δ directly
induces the expression of its cognate intracellular lipid
binding protein FABP5.
2.4. The FABP5/PPARβ/δ Pathway Enhances Proliferation
of PC3M Prostate Cancer Cells. FABP5 and PPARβ/δ isPPAR Research 5
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Figure 4: The FABP5/PPARβ/δ pathway enhances prostate cancer cell proliferation and transformation. (a) PC3M cells that stably express
shFABP5 were cultured in a 24 well plate (2500 cells/well) and treated with vehicle or GW 0742 (1μM). Cells were counted at the denoted
days. Data are mean±SEM (n = 3). Inset: immunoblotting demonstrating low FABP5 level in shFABP5-expressing. (b) PC3M cells were
transfectedwithavectorharboringPPARβ/δsiRNA.Fourdayslater,wereculturedina24wellplate(2500cells/well) andtreatedwithvehicle
or GW 0742 (1μM). Cells were counted at the denoted days. Inset: Q-PCR analyses demonstrating low PPARβ/δ in cells transfected with
SiRNA towards the receptor. (c) Colony formation assays were conducted in the absence or presence of GW0742 (1μM). Cells were cultured
in 2% agarose for 29 days (see Materials and methods for details). Media was replenished every 4 days. Colonies were visualized by staining
with 0.005% crystal violet and counted under a light microscope. Data are mean±SEM (n = 3).
involved in enhancing cell proliferation and survival in
keratinocytes and some mammary carcinoma cells [5, 13,
30].Toexaminetheinvolvementofthepathwayinregulation
of prostate cancer cell growth, the eﬀect of treatment
of PC3M cells with GW0742 was examined. The data
(Figure 4(a)) showed that GW0742 markedly enhanced cell
proliferation as early as day 2. The PPARβ/δ-selective ligand
also increased the proliferation of the less malignant 22Rv1
(data not shown). Strikingly, reducing the expression level
of either FABP5 (Figure 4(a))o rP P A R β/δ (Figure 4(b))
markedly retarded cell proliferation as well as hampered
the proliferative response to GW0742. To monitor eﬀect
of the FABP5/PPARβ/δ pathway on the ability of PC3M
cells to form colonies in a sub strata-free environment,
an established hallmark of tranformation, cells that stably
express scrambled shRNA or shRNA towards FABP5 were
generated and colony formation assays were carried out
in the absence or presence of GW0742 (Figure 4(c)).6 PPAR Research
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Figure 5: A model for the cooperation between FABP5 and
PPARβ/δ which enhances prostate cell survival and proliferation.
Upon binding to a cognate ligand, FABP5 translocates to the
nucleus where it directly delivers the ligand to its cognate nuclear
receptor, PPARβ/δ. Activation of PPARβ/δ results in upregulation
of FABP5. A positive feedback loop is thus established: PPARβ/δ
activationinducestheexpressionofFABP5which,inturn,enhances
the transcriptional activity of the receptor. The FABP5/PPARβ/δ
pathway induces the expression of PPARβ/δ target genes involved
in cell survival, for example, PDK1, and growth and angiogenesis,
for example, VEGF, and thus contributes to prostate cancer
development.
The data demonstrated that GW0742 signiﬁcantly increased
the number of colonies, and that downregulation of FABP5
inhibited colony formation both in the absence and presence
of ligand.
3. Discussion
The data presented above demonstrate that FABP5, which
functions to selectively deliver ligands to the nuclear receptor
PPARβ/δ, is under the direct control of its cognate nuclear
receptor in prostate cancer cells. In the presence of an
activating ligand, FABP5 is imported into the nucleus where
it directly “channels” the ligand to PPARβ/δ [5, 18]. In turn,
in prostate cancer cells, activated PPARβ/δ upregulates the
expression of FABP5. The resulting positive-feedback loop
augments the overall activity of the FABP5/PPARβ/δ path-
way, leading to eﬃcient induction of PPARβ/δ target genes
involved in cell proliferation and survival and supporting
prostate cancer cell growth (Figure 5). Hence, similarly to its
ability to enhance the proliferation of keratinocytes [5, 11,
30]andtodrivemammarytumorgrowthinthebreastcancer
mouse model MMTV-neu [5, 13], the FABP5/PPARβ/δ
pathway induces prostate cancer cell growth (Figure 4).
These data suggest that antagonists for FABP5 or PPARβ/δ
may be eﬃcacious therapy and perhaps prevention of some
cancers. The identiﬁcation of a selective antagonist for
PPARβ/δ h a sb e e nr e p o r t e d[ 31] but, to the best of our
knowledge, the ability of the compound to inhibit cancer cell
growth has not yet been examined. No antagonist for FABP5
is currently available. However, a synthetic inhibitor for the
related protein FABP4 has been developed and was shown to
improve insulin resistance and atherosclerosis in mice [32].
Intracellular lipid-binding proteins may thus be targeted for
therapy and prevention of disease. Eﬀorts to identify a small
molecule inhibitor for FABP5 are ongoing.
Of the fourteen known intracellular lipid binding pro-
teins (iLBPs), four have been shown to cooperate with
speciﬁc nuclear receptors. It was reported that CRABP-II
delivers RA to RAR, and that FABP1, FABP4, and FABP5
shuttle cognate ligands to PPARα,P P A R γ,a n dP P A R β/δ,
respectively [7, 8, 14–18, 33, 34]. Cooperation of iLBPs with
nuclear receptors requires that the binding proteins be able
to move in and out of the nucleus and that they do so
in a ligand-dependent manner. Indeed, a ligand-controlled
nuclear localization signal has been identiﬁed in CRABP-
II [17] and FABP4 [35] and a constitutive nuclear export
signal was found in FABP4 [35]. Sequence homology con-
siderations suggest that such signals are present in some but
not all ILBPs. Hence, some iLBPs may play roles outside the
nucleus and that their functions may be unrelated to those of
nuclear receptors. It is interesting to note that the promoters
of three of the iLBPs known to function in conjunction with
nuclear receptors harbor response elements for their cognate
receptors.Thus,theCRABP-IIpromoterharborsaconsensus
RARE [36], the expression of FABP4 is directly regulated by
PPARγ in adipocytes [37], and, as shown here, FABP5 is a
direct target gene for PPARβ/δ in prostate cancer cells. The
ability of these receptors to induce the expression of their
binding proteins is however cell-speciﬁc. For example, while
RAR upregulates CRABP-II in human skin ﬁbroblasts [36],
it does not induce the expression of the protein in rat uterus
[38]. Similarly, activated PPARβ/δ eﬀectively upregulates
FABP5 expression in prostate cancer cells (Figure 2) but has
little eﬀect on the expression of the gene in adipocytes (our
unpublished observations). The basis for the cell speciﬁcity
of the feedback-loop between binding proteins and their
cognate nuclear receptor remains to be clariﬁed.
4.MaterialsandMethods
4.1. Reagents. Plasmid harbouring FABP5shRNA was ob-
tained from Open Biosystems (172-0471-C-3 — V2LHS-
131713). Oligonucleotides for siPPARβ/δ were from Applied
biosystems). Transfections were performed using superfect
transfection reagent as per manufacturers’ protocol. Anti-
bodies against RXR (sc-774) and PPAR-β/δ (sc-7197), rabbit
IgG (sc-2027), and protein A/G agarose (sc-2003) were
purchased from Santa Cruz Biotechnology Inc. Antibodies
against FABP5 (AF3007) and PDK1 (61107) were obtained
from R&D Systems and Transduction Laboratories, respec-
tively.
4.2. Cells. PC3M and 22Rv1 cells were cultured in L-
Glutamine containing RPMI medium supplemented with
10% fetal calf serum, penicillin (100U/ml), and strepto-
mycin (100mg/ml) (Invitrogen Life Sciences, Carlsbad, CA).
Prior to treatment with ligands, cells were grown in medium
containing 10% charcoal treated serum for 12hr. DependingPPAR Research 7
on whether mRNA or protein analysis was to be performed,
cells were exposed to ligands for 4hr or 16hr, respectively. In
proliferation, colony formation, wound healing assays, and
ligand supplementation were replenished every 24hr.
4.3. Bioinformatics. Primers were designed using the
primer3 primer design software (http://frodo.wi.mit.edu/).
Primer selectivity was validated using a nucleotide blast
program (http://blast.ncbi.nlm.nih.gov/Blast) and primers
purchased from Integrated DNA Technologies (Coralville,
IA).
4.4. Immunoblots. Total cell protein was extracted using
RIPA buﬀer (25mM Tris-HCl, 150mM NaCl, 1% NP40, 1%
sodiumdeoxycholate,and0.1%SDS).Proteinswereresolved
by electrophoresis on 10% SDS-PAGE gels and transferred
onto Immobilon-Psq membrane (Millipore). Membranes
were incubated with primary antibodies (1hr), followed
by 3 washes with Tween-TBS, and incubation with HRP
conjugated antibodies. Protein expression was detected by
exposure to ECL and exposed to XR-B x-ray ﬁlm. Band
intensities were quantiﬁed using AlphaImager 2000 software
(Alpha Innotech).
4.5. Transcriptional Activation Assays. To generate reporter
plasmids, the promoter of FABP-5 containing the identiﬁed
putative PPREs was ampliﬁed by PCR and KpnI and MluI
restriction sites overhangs were added using the primers
5
 -CCGGGTACCTCAGAGCTCCATCACAGCTAC-3
 (sense)
and 5
 -CCGACGCGTACTGCAGGAAGTGATTGATCG-3
 
(antisense).PCRproductswereintegratedintoanpRL-PGL3
reporter vector. The pRL-PGL3 vector was transformed into
XL1 Blue competent cells, colonies selected, ampliﬁed and
veriﬁed by DNA sequencing. PC3M cells were transfected
with pRL-PGL3 reporter vector, a plasmid encoding β-
galactosidase, and expression vectors for PPARα, β,o r
γ. Cells were treated with ligands for 24hrs, lysed and
luciferase activity measured using the luciferase assay
system. Luciferase activity was normalized to β-galactosidase
activity.
4.6. Quantitative Real-Time PCR. Total RNA was extracted
using Trizol (Invitrogen), and cDNA generated using a high
capacity cDNA reverse transcription kit (Applied Biosys-
tems).mRNAlevelsweremeasuredbyQ-PCRusingTaqman
chemistry and assays on demand probes (Applied Biosys-
tems) for FABP5 (Hs2339439 g1), ADRP (Hs00765634 m1),
PDK1 (Hs01561850 m1), PPARβ/δ (Hs00606407 m1), and
VEGF (Hs00173626 m1). 18s ribosomal RNA was used as a
loading control.
4.7. Chromatin Immunoprecipitation. PC3M cells were
grown to 80% conﬂuency in charcoal treated serum for
24hr prior to ligand treatment. Proteins were crosslinked
to DNA using 10% formaldehyde (20min, 37◦C). Reaction
was stopped with glycine (125mM, 5min 4◦C), cells were
washed three times in ice cold PBS, scraped, lysed (1% SDS,
10mmol/L EDTA, 50mM, Tris at pH 7.9, 1mM DTT, leu-
peptin,pepstatinA,andaprotinin),incubated(4◦C,30min),
and sonicated. One ﬁfth of the sample was stored as input,
whereas the remaining samples were diluted with 0.5% Tri-
ton X-100, 2 mMEDTA, 2mM Tris (pH 7.9), 150mM NaCl,
1mM DTT, protease inhibitors, and salmon sperm DNA,
and precleared (1hr, 4◦C) with protein A beads. Following
centrifugation, supernatants were incubated with appropri-
ate antibodies overnight and protein A beads were added
(2hr). Beads were washed with 0.25% NP40, 0.05% SDS,
2mMEDTA,20mMTris(pH8),250mMNaClandprotease
inhibitors and with TE buﬀer, re-suspended in NaHCO3
containing 1% SDS, and the crosslink reversed (12hr, 65◦C).
Proteins were degraded by proteinase K (80μg/ml, 1hr),
DNA puriﬁed by phenol-chloroform extraction and appro-
priate regions ampliﬁed by PCR. PCR primers for PPRE4:
sense, 5
 -CCCAACAGGGATAAAATCCT-3
 ; antisense, 5
 -
TACCCGGACCAATCGATTA-3
 .
4.8. Colony Formation Assays. A basement layer of a 1:1
mixture of 2% agarose in Tris-borate buﬀer and RPMI
1640 medium was cast in a 6-well plate at 4◦C. Cells were
suspended in the same agarose-RPMI mixture at room
temperature at a density of 5×103 cells/ml. The mixture was
decanted onto the preset basement gel layer and incubated
at 4◦C to solidify. Once set, the cells in the plates were grown
for29days.Mediawerereplenishedevery4days.Tovisualize
colonies, cells were stained with 0.005% crystal violet and
counted under a light microscope.
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